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INTRODUCTION: Survival in small cell lung cancer (SCLC) is limited by the development of chemoresistance. Factors associated with
chemoresistance in vitro have been difficult to validate in vivo. Both Bcl-2 and b1-integrin have been identified as in vitro
chemoresistance factors in SCLC but their importance in patients remains uncertain. Tissue microarrays (TMAs) are useful to validate
biomarkers but no large TMA exists for SCLC. We designed an SCLC TMA to study potential biomarkers of prognosis and then used
it to clarify the role of both Bcl-2 and b1-integrin in SCLC.
METHODS: A TMA was constructed consisting of 184 cases of SCLC and stained for expression of Bcl-2 and b1-integrin. The slides
were scored and the role of the proteins in survival was determined using Cox regression analysis. A meta-analysis of the role of Bcl-2
expression in SCLC prognosis was performed based on published results.
RESULTS: Both proteins were expressed at high levels in the SCLC cases. For Bcl-2 (n¼140), the hazard ratio for death if the staining
was weak in intensity was 0.55 (0.33–0.94, P¼0.03) and for b1-integrin (n¼151) was 0.60 (0.39–0.92, P¼0.02). The meta-analysis
showed an overall hazard ratio for low expression of Bcl-2 of 0.91(0.74–1.09).
CONCLUSIONS: Both Bcl-2 and b1-integrin are independent prognostic factors in SCLC in this cohort although further validation is
required to confirm their importance. A TMA of SCLC cases is feasible but challenging and an important tool for biomarker
validation.
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Despite initial good response rates to chemotherapy (Amarasena
et al, 2008), the overall 5-year survival rate for small cell lung
cancer (SCLC) is only 5% (Hann and Rudin, 2007). This
paradoxically poor survival rate is due to the fact that patients
almost invariably relapse with disease that is resistant to
chemotherapy; relapse rates of up to 95% have been reported
(Huisman et al, 1999). Treatment refractory disease is the major
factor that limits improvement in survival rates for this type of
lung cancer. As very few patients with SCLC have surgical
resection, tumour samples available for research are usually
restricted to small biopsy specimens. Consequently, much of the
study of SCLC biology has been accomplished using a limited
repertoire of cell lines generated from tumours, frequently derived
after initial treatment (Carney et al, 1985). High expression of the
cell adhesion protein b1-integrin and the anti-apoptotic protein
Bcl-2 have both been associated with increased cell survival in
in vitro models of SCLC (Sethi et al, 1999; Pardo et al, 2002;
Sartorius and Krammer, 2002) but in vivo confirmation of an
important role in patients with SCLC is sparse. For b1-integrin,
there is evidence from a small Japanese study that low expression
is associated with a better outcome (Oshita et al, 2002). For Bcl-2,
no relationship between expression levels and survival has been
confirmed in SCLC (Martin et al, 2003; Ilievska Poposka et al, 2008).
Despite this, trials of treatment targeted at Bcl-2 in SCLC are in
progress (Hann et al, 2008; Rudin et al, 2008; Shoemaker et al, 2008).
Tissue microarrays (TMAs) were developed to allow high-
throughput analysis of protein expression in tumour tissues
(Kononen et al, 1998). The use of TMAs to validate biomarkers of
outcome in tumour tissue is well established (Hassan et al, 2008).
Here, we report the first SCLC TMA for biomarker validation,
which we have used to investigate a role for both b1-integrin and
Bcl-2 expression in the survival of patients with SCLC.
MATERIALS AND METHODS
Ethical approval for the use of samples and data collection was
granted by the local Research Ethics Committee. All cases of SCLC
diagnosed at Papworth Hospital (Cambridge, UK) between 1998
and 2005 were identified from hospital records and the formalin
fixed, paraffin-embedded biopsy tissue samples were retrieved
from the pathology department store along with their associated
histology slides. Clinical data relating to the cases was compiled
from a database held at Papworth Hospital. Survival data were
confirmed from records of deaths or via the family doctor of the
patient concerned.
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sHistology slides were examined, and areas of tumour tissue were
marked. Whenever possible, at least two areas of tumour tissue
were marked on each slide. In some cases, multiple blocks taken
from the same tumour were available, and a slide from each block
was included. The marked slides were scanned onto the Ariol SL50
system (Genetix, Gateshead, UK) for ease of comparison with
the cut surfaces of the paraffin blocks and 0.6mm cores of the
marked areas were taken using a Beecher Manual Tissue Arrayer 1
(Beecher Instruments, Sun Prairie, WI, USA). The cores (including
marker cores for orientation and cores of control material from
patients without cancer and from areas of normal appearing tissue
from the SCLC tissue blocks) were assembled into a TMA and cut
across four slides to enable full representation.
Slides were stained on a BondMax Autostainer (Leica, Milton
Keynes, UK). Antigen retrieval was performed at 1001C in Bond
ER2 diluent, followed by a 15-min incubation with primary
antibody at room temperature, 8-min incubation using a polymer
secondary system (Leica) followed by developing with Diamino-
benzidine using copper enhancement. Haematoxylin counter-
staining was performed automatically on the Bond system, and
finally, the slides were dehydrated, cleared and mounted using a
Leica ST5020 attached coverslipper CV5030 (Leica). b1-Integrin
was detected using CD29 antibody diluted 1:100 (Novocastra,
Newcastle, UK), and Bcl-2 was detected using Clone 124 antibody
diluted 1:200 (Dako, Glostrup, Denmark). The slides were scanned
onto the Ariol system for analysis.
Scoring was performed simultaneously by two observers (one of
whom was a senior pulmonary histopathologist) blinded to the
clinical data, and a consensus score reached for each tissue core.
For each core and for each antibody, both extent and intensity of
tumour staining were evaluated on a scale from 0 to 3 after the
method by Allred et al (1998). For b1-integrin, extent was scored
with 0 if o10% of tumour cells positive, 1¼10–25%, 2¼25–50%
and 3 if 450% (Oshita et al, 2002; Yao et al, 2007). For
Bcl-2, extent was scored with 0 if o10% of tumour cells positive,
1¼10–50%, 2¼50–75% and 3 if 475%. For both proteins,
intensity was scored as 0¼no staining, 1¼low-intensity staining,
2¼medium-intensity staining and 3¼high-intensity staining
(Figure 1). Data analysis was performed with SPSS v17.0 (SPSS
Inc., Woking, UK). Univariable survival analysis used the log rank
test (LR), and multivariable analysis was performed by Cox
regression using a forward stepwise model based on likelihood
ratios. Results were displayed as Kaplan–Meier plots. Categorical
outcomes were analysed using the w
2-test.
Initial analysis used previously published criteria to define cases
as having positive or negative expression of each protein, with a
cutoff of 10% of cells with staining for Bcl-2 (Martin et al, 2003)
and 25% for b1-integrin (Oshita et al, 2002). Further analysis was
based on plotting survival for each extent or intensity score and
examining the survival curves to see if the cases could reasonably
be dichotomised into good- and poor-prognosis groups.
A meta-analysis was performed of studies, which compared
Bcl-2 staining by immunohistochemistry with survival for patients
with SCLC. This was based on eight published studies along with
the results from the current study (Kaiser et al, 1996; Takayama
et al, 1996; Dingemans et al, 1999; Maitra et al, 1999; Zereu et al,
2003; Paik et al, 2006; Ilievska Poposka et al, 2008; Lee et al, 2008).
Hazard ratios for death if Bcl-2 negative were taken from
multivariable analysis in the original paper. If the original
publication did not contain these data, it was calculated from
the data presented by Martin et al (2003) or calculated using the
indirect method by Parmar et al (1998). A summary hazard ratio
was calculated, and a forest plot was created using the R package
‘rmeta’ (Lumley, 2009).
RESULTS
In all, 203 cases of SCLC diagnosed at Papworth Hospital between
1998 and 2005 were identified from the Pathology department
archive. Of these 203 cases, 184 had tissue on at least one level of
the TMA. Overall survival data were complete to the end of 2008.
Characteristics of the cohort are shown in Table 1. Baseline
demographic characteristics that were found to be significant
prognostic factors in univariable analysis were stage, age,
performance score and first-line treatment. Cox regression analysis
was performed to identify independent prognostic variables. For
each variable, a log minus log plot was created and confirmed
proportionality of hazards. The Cox regression model had 153
patient events in 166 patients with a complete data set and
included stage and first-line treatment as independent variables
(Po0.0005). Median survival was 13.5 months (9.8, 17.2 months)
for patients with limited stage disease and 5.5 months (3.9, 7.2
months) for extensive stage.
For Bcl-2, 140 cases, of the possible 184 cases present on the
whole TMA, had sufficient stained tumour tissue to evaluate
staining at the level of the TMA used. There was no evidence of a
difference in baseline characteristics or in survival between cases
whose staining could be assessed and the remaining cases. There
were 58 cases with more than one core of tumour on the TMA;
49 cases had 2 cores. Where more than one core was present and
the scores were not identical, the modal score was taken for each
Intensity 1-integrin  
3
2
1
0
Bcl-2
Figure 1 Staining pattern of SCLC cores for b1-integrin and Bcl-2.
The TMAs were stained and scanned onto the Ariol system. Consensus
scoring was performed by two blinded observers. Scores were assigned
based on staining intensity. The images shown are from the Ariol system
and were cropped to size using Photoshop.
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stumour; this happened in seven cases. Where this was not possible,
the highest score was taken and this occurred in 27 cases. In the
remaining 24 cases, all the cores were scored identically.
The majority of cases had extensive staining for Bcl-2. There was
only one case where o10% of cells were stained and 82% (115 out
of 140) of evaluated cases had 450% cells positive. No differences
in survival were detectable based on differences in staining extent.
Survival analysis revealed that the most informative categorisation
by intensity was with a cutoff between low (intensity score 1) and
medium intensity (score 2). Therefore, cases were reclassified as
either high-intensity staining (score 2 or 3) or low-intensity
staining. Analysis of survival showed that patients with low-
intensity staining survived for longer (LR¼8.09, P¼0.004,
Figure 2A), and this relationship was maintained in the sub-group
treated with chemotherapy (n¼95, LR¼5.22, P¼0.022). Cox
regression analysis with age (as a continuous variable), sex, stage,
performance score, first-line treatment and staining intensity as
the input variables confirmed a significant role for Bcl-2 as an
independent predictor of survival in this cohort (Figure 2B).
The hazard ratio for death in patients with low-intensity staining
was 0.55 (95% CI¼0.33, 0.94, P¼0.03, n¼117). There was no
evidence of an effect of Bcl-2 staining on progression-free survival,
and Bcl-2 status was not predictive of response to chemotherapy.
Only 151 cases had tumour tissue available to analyse for
b1-integrin staining at the TMA level used. Baseline characteristics
and survival were not different for those patients from the whole
cohort who had cores stained for b1-integrin in comparison to
those who did not. For b1-integrin, differences in staining extent
were not predictive of survival and only 8.6% (13 out of 151) of
cases scored had o50% of cells stained. On the basis of the
Kaplan–Meier plot of all categories of b1-integrin staining
intensity, intensity was dichotomised into those with high-
intensity staining (score of 3) and those with lower-intensity
staining (score 0–2). Using this classification, high-intensity
staining carried a worse prognosis (LR¼3.85, P¼0.05;
Figure 3A). In Cox regression analysis, only stage, first-line
treatment and staining intensity were retained in the model
(n¼121; Figure 3B). Patients with a low intensity of staining had a
hazard ratio of death of 0.60 (0.39, 0.92) compared with patients
with high intensity (P¼0.019). However, b1-integrin staining
showed no evidence of being predictive of response and had
no impact on progression-free survival in those treated with
chemotherapy.
Data for survival based on intensity of b1-integrin staining and
Bcl-2 staining were combined. Cases were categorised based on low
or high intensity of staining for each antibody into three groups.
The ‘good-prognosis’ group (n¼9) had low-intensity staining for
both antibodies, the ‘poor-prognosis’ group (n¼74) had high-
intensity staining for both antibodies and the ‘intermediate-
prognosis’ group had discordant staining for the two antibodies
with one low and one high intensity (n¼47). Univariable survival
analysis revealed that the good-prognosis group had a median
survival of 12.5 months (10.29, 14.71) compared with 9.18 months
(8.12, 10.24) for the intermediate group and 6.8 months (5.49, 8.06)
in the poor-prognosis group (LR¼8.98, P¼0.011; Figure 4).
Table 1 Characteristics of the patients in the whole cohort and those
with cores stained for Bcl-2 and b1-integrin
TMA Bcl-2 b1-integrin
Total cases 184 140 151
Sex (male %) 63 62 63
Age (years)
Mean (s.d.) 67.17 (10.00) 67.27 (9.92) 67.34 (9.93)
Stage (%)
Limited 44 44.5 45
Extensive 54 54.5 52
Unknown 2 1 3
Performance score (%)
0, 1 53 57 53
X2 30 26.5 28.5
Unknown 17 16.5 18.5
First-line treatment (%)
Chemotherapy 66 68 66
Radiotherapy 15 15 16
Surgery 2 2.5 3
Supportive care 12 11 10
Unknown 5 3.5 5
Abbreviations: TMA¼tissue microarray; s.d.¼standard deviation.
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0.0
High censored
Low censored
High
Low
Intensity
Low 27 14 9 7 4 3 2
High 113 30 13 10 5 3 0
Variable Hazard ratio (HR) 95% CI for HR P value
Bcl-2 intensity (low vs high) 0.55 0.33–0.94 0.03
First-line treatment
Chemotherapy vs BST 0.03 0.01–0.07 0.00
XRT vs BST 0.13 0.05–0.33 0.00
Surgery vs BST 0.03 0.01–0.20 0.00
Sex (F vs M) 1.54 1.02–2.31 0.04
Stage (L vs E) 0.47 0.31–0.70 0.00
Figure 2 Analysis of the role of Bcl-2 staining in survival in SCLC.
(A) Overall survival analysis was performed based on the patients who had
Bcl-2 staining scored on the TMA (n¼140). Variables were assessed by
Kaplan–Meier analysis and survival curves were plotted. The variables that
were significant in the whole patient cohort remained significant in this
cohort. The Kaplan–Meier plot for Bcl-2 intensity (n¼140) is shown,
P¼0.004 by log rank test. The numbers of patients at risk in each group at
each time point are shown below the plot. (B) Variables that were positive
in univariable analysis were used for Cox regression analysis. A multivariable
model was constructed using a forward stepwise method based on
likelihood ratios. Four variables were independent predictors of outcome;
stage, sex, first-line treatment and intensity of staining for Bcl-2 (P¼0.03,
n¼117). Age at diagnosis and PS were rejected. XRT¼radiotherapy;
BST¼best supportive care; L¼limited; E¼extensive; HR¼hazard ratio;
CI¼confidence interval.
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individual antibodies, the ‘good-prognosis’ group had a hazard
ratio for death of 0.28 (0.11, 0.67), but the survival difference
between the intermediate and poor groups was lost (n¼108).
The meta-analysis of the effect of Bcl-2 negativity on survival
identified 516 deaths in a cohort of 673 cases, including the data
presented in the current paper (Figure 5). The overall hazard ratio
was 0.91, indicating better survival for patients negative for Bcl-2
staining but this was not statistically significant.
DISCUSSION
This paper describes the first dedicated SCLC TMA for biomarker
discovery and validation to be reported. The cohort of
patients studied is an unselected group of SCLC patients
representative of the spectrum of disease seen and treated in the
UK (El-Helw et al, 2008). Three groups have published data from a
TMA with SCLC cases previously, but all used surgical samples of
SCLC to construct the TMA, and this makes them unrepresentative
of the clinical disease spectrum (Donati et al, 2004; Nitadori et al,
2006; Chiappori et al, 2010). The Japanese group included 14
surgically resected cases with 39 cases of large-cell neuroendocrine
cancer on a TMA designed to compare the immunohistochemical
staining patterns of the two diseases (Nitadori et al, 2006). An
Italian group obtained tissue from 54 cases of SCLC treated by
surgical resection over a 21-year period and looked at the accuracy
of biomarker staining on the TMA in comparison to ‘whole
sections’ of tissue (Donati et al, 2004). They found that in
comparison to whole sections, the TMA had an accuracy of 87%,
and the shortfall was attributed to small cores of tissue not
representing the whole tumour well (Donati et al, 2004). They did
not present data on the accuracy of the TMA compared with
sections cut from biopsies, which like the TMA cores, may not
represent the whole tumour accurately, and they did not look at
the impact of staining in the TMA on clinical end points. Their
conclusion was that a TMA could not replace examination of tissue
sections in the diagnosis of SCLC. The most recent paper reported
data from a commercially made TMA including 100 cases of SCLC
(Chiappori et al, 2010) and described the pattern of specific
marker expression using an automated analysis system. The
origins of the tissue used for the TMA was unclear in terms of
collection method, but they were probably surgical samples, and 23
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Figure 3 Analysis of the role of b1-integrin staining in survival in SCLC.
(A) Overall survival analysis was performed based on the patients who had
CD29 (b1-integrin) staining scored on the TMA (n¼151). Variables were
assessed by Kaplan–Meier analysis and survival curves were plotted. The
variables that were significant in the whole patient cohort remained
significant in this cohort. The Kaplan–Meier plot for b1-integrin intensity
(n¼151) is shown, P¼0.05 by log rank test. The numbers of patients
at risk in each group at each time point are shown below the plot.
(B) Variables that were positive in univariable analysis were used for Cox
regression analysis. A multivariable model was constructed using a forward
stepwise method based on likelihood ratios. Three variables were
independent predictors of outcome; stage, first-line treatment and intensity
of staining for b1-integrin (P¼0.02, n¼121). Age at diagnosis, sex and PS
were rejected. XRT¼radiotherapy; BST¼best supportive care;
L¼limited; E¼extensive; HR¼hazard ratio; CI¼confidence interval.
Good 9 5332 22
Intermediate 47 17 11 8 3 2 0
Poor 74 20 7 5 3 2 0
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Figure 4 Combining results of b1-integrin staining and Bcl-2 staining
identifies three groups with differing prognoses. Cases were grouped based
on expression of b1-integrin and Bcl-2 into cases where (1) both proteins
had high expression (n¼74; predicted to have poor prognosis), (2) both
had low expression (n¼9; predicted to have good prognosis) and (3)
those with discordant expression levels (n¼47; predicted to have
intermediate prognosis). Survival was plotted by the Kaplan–Meier method
showing significant differences between the three groups (log rank¼8.98;
P¼0.01). The numbers of patients at risk in each group at each time point
are shown below the plot.
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sof the 100 cases were mixed SCLC and other histologies (Chiappori
et al, 2010; Shanghai Outdo Biotech Ltd.).
Traditionally, surgical specimens have provided the tissue cores
for TMA construction, as they provide an easy to handle source of
large quantities of tissue for most tumours. Small Cell Lung Cancer
is a special case as resection is not part of the usual clinical
management of patients. The biopsies used for diagnosis are small
making them difficult to handle and frequently have o50%
tumour in them (Coghlin et al, 2010). The reason analysis of
prognostic factors in SCLC has not been studied using a TMA
previously is almost certainly the technical difficulty of construct-
ing a TMA from small biopsy samples. In the TMA constructed
from surgical resections of SCLC, 13.4% of cores were lost from the
donor block to the recipient TMA block (Donati et al, 2004). In the
current TMA, 203 cases were identified, and 184 cases had tissue
on the TMA at some level. The small biopsy samples are not
perfectly aligned on the TMA and do not contain homogenous
tumour samples. This means that at a given level of the TMA,
tumour tissue may be present but then absent at deeper levels and
present again at even deeper levels. This explains why the sample
size was 151 cases for b1-integrin but only 140 for Bcl-2. However,
there was no evidence of this dropout altering the characteristics of
the study population in terms of demographics or survival.
Dropout of cases must be tolerated as limiting analysis to
surgically resected tumours makes the cohort unrepresentative of
clinical disease. Dropout of cases is an important consideration
when prospectively planning TMA construction to ensure an
adequate sample size for the planned analyses. Practically, the
small numbers of available cases in SCLC means that minimisation
of dropout during construction of the TMA is paramount and
requires a high degree of technical skill. Ideally, multiple cores of
each tumour would be placed on the TMA to minimise
misrepresentation, but this is not a realistic proposition in SCLC
due to lack of sufficient tissue.
For both Bcl-2 and b1-integrin, there is good evidence that they
can protect SCLC cells from chemotherapy-induced apoptosis
in vitro. However, confirmation that this is important in vivo is
lacking (Sethi et al, 1999; Sartorius and Krammer, 2002). Our
primary data, which equals the largest previous study in terms of
statistical power, found that low Bcl-2 expression was an
independent predictor of improved prognosis in SCLC, which
supports the hypothesis driving the study of the use of Bcl-2
antagonists in SCLC (Rudin et al, 2008; Shoemaker et al, 2008).
The meta-analysis performed in this study, which builds on the
work by Martin et al (2003), shows that no clear relationship
between Bcl-2 expression and survival has yet been identified.
Low expression of b1-integrin was also shown to be an
independent marker of better prognosis in the current study,
confirming the work by Oshita et al (2002). This is consistent with
the in vitro findings that extracellular matrix proteins can activate
phosphatidylinositol-3-kinase/AKT dependent pro-survival path-
ways via binding to b1-integrin (Sethi et al, 1999). Phosphatidy-
linositol-3-kinase/AKT signalling is able to activate Bcl-2 and
signalling via b1-integrin has been linked previously to the
promotion of cell survival via Bcl-2 upregulation (Zhang et al,
1995; Vivanco and Sawyers, 2002). In the current study, combining
the staining results for both proteins allowed the identification of a
small subset of patients with a particularly good prognosis.
The definition of positive staining for each protein is of key
importance in assessing the validity of the results obtained. Overall,
p r o t e i ne x p r e s s i o ni nat i s s u ec a nb ec o n s i d e r e dt oh a v et w oa s p e c t s ,
extent of staining (the number of cells that exhibit staining) and
intensity of staining (the amount of staining in positive cells). Either
parameter, or both, or neither, may have prognostic relevance for a
given protein in a specific situation. Extent is commonly used to
define positive staining for the purposes of survival analysis as
intensity of staining can be influenced by subtle differences in the
staining process between different batches of sections processed.
This problem does not occur when staining a TMA. For both Bcl-2
and b1-integrin, extent of staining is the criterion that has been used
previously to define positive staining with a cutoff of 10% of tumour
cells for Bcl-2 and 25% for b1-integrin. However, it is apparent
from Figure 5 that the 10% cutoff, used in all the studies except those
of Kaiser et al (1996) (50% cutoff) and Lee et al (2008) (both
extent and intensity of staining), has not been validated, as it does not
give consistent results and the 25% cutoff for b1-integrin has
only been reported in a single cohort. In the current study, extent
of staining was not found to be informative for survival but
unbiased examination of survival by intensity of staining was.
A plausible explanation for the lack of discrimination of
staining extent compared with intensity in our study would be
increased sensitivity of the staining methods for the detection of
positive cells. Increased sensitivity may be due to better antigen
retrieval, the use of automated staining or better signal amplification
systems (such as the polymer secondary system we used). For Bcl-2, it
is unlikely to be due to the primary antibody as the Clone 124
antibody is a standard, well validated, antibody that is used widely
(Martin et al, 2003).
A survival advantage for patients with low levels of expression of
both Bcl-2 and b1-integrin was demonstrated, but in both cases,
the low expression group was relatively small. This leads to the
possibility of the data being ‘over-fitted’ and the results an artefact.
This and the caveats in this study relating to the post hoc definition
of the groups with differing survival would both be addressed
by replication in an independent cohort of samples. This is the first
large SCLC TMA to be reported in the literature and was
technically difficult to construct. Replication in an independent
sample set is an important future challenge.
Study
Kaiser (1996)
Takayama (1996)
Dingemans (1999)
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Ilievska (2008)
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1.32
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Figure 5 Forest plot of role of Bcl-2 in SCLC survival from the literature. Previous studies were combined in a meta-analysis with the results of the current
study and a forest plot generated. The summary hazard ratio (HR) suggests better survival in Bcl-2-negative cases but does not reach significance. Box size is
proportional to accuracy of estimate. CI¼confidence interval.
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for the validation of in vitro findings and biomarker studies is
feasible in SCLC. We have used our TMA to confirm that both
b1-integrin and Bcl-2 are independent markers of adverse
prognosis in SCLC. For both biomarkers, we report the most
statistically powerful analysis done in SCLC patients in a cohort
treated in line with current best practice. The results highlight
these two molecules as potentially useful targets for future work.
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